Innohale Therapeutics

Company Overview

Snapshot

Founded in April 2020 by Dan Rappaport and Yaacov Nitzan, Innohale Therapeutics operates with 1–10 employees. The company is currently in the R&D product stage and ceased operations in January 2025.

Business overview

Innohale Therapeutics specializes in developing inhaled nitric oxide (iNO) delivery solutions designed for the treatment of various respiratory conditions, including those stemming from COVID-19, and severe lung infections. Their core technology focuses on producing iNO from ambient air, aiming to enhance treatment accuracy while simultaneously reducing associated costs and logistical burdens. The company operates within the Health Tech & Life Sciences sector, specifically targeting the medical devices and life support industries.

Company Intelligence Q&A

What is Innohale Therapeutics' primary focus?

Innohale Therapeutics focuses on developing inhaled nitric oxide (iNO) delivery solutions for respiratory conditions and severe lung infections.

When was Innohale Therapeutics founded?

Innohale Therapeutics was founded in April 2020.

Who are the founders of Innohale Therapeutics?

The co-founders of Innohale Therapeutics are Dan Rappaport and Yaacov Nitzan.

What is the current operational status of Innohale Therapeutics?

Innohale Therapeutics ceased to operate in January 2025.

What is the product stage of Innohale Therapeutics' technology?

Innohale Therapeutics' technology is currently in the R&D stage, focusing on developing inhaled nitric oxide delivery solutions.